Does the media prefer EKF or NIOX?

In the previous week, EKF Diagnostics and EKF Diagnostics both had 1 articles in the media. EKF Diagnostics' average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EKF Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NIOX Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TSTL or EKF?

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is TSTL or EKF more profitable?

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% EKF Diagnostics 4.12% 3.01% 5.27%

Do analysts prefer EKF or BVC?

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe EKF Diagnostics is more favorable than BATM Advanced Communications. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 BATM Advanced Communications 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

EKF Diagnostics (EKF) Competitors

GBX 26 +0.90 (+3.59%)

As of 11:56 AM Eastern

Compare

EKF vs. NIOX, TSTL, SPEC, CREO, and BVC

Should you buy EKF Diagnostics stock or one of its competitors? EKF Diagnostics's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), INSPECS Group (SPEC), Creo Medical Group (CREO), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does EKF Diagnostics compare to NIOX Group?

EKF Diagnostics (LON:EKF) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
NIOX Group	14.37%	10.14%	3.95%

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 34.62%. NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 34.38%. Given EKF Diagnostics' higher probable upside, research analysts plainly believe EKF Diagnostics is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

EKF Diagnostics has a beta of 0.513, suggesting that its share price is 49% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

NIOX Group has lower revenue, but higher earnings than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.17	£4.68M	£0.47	55.32
NIOX Group	£48.70M	5.53	£995.88M	£1.64	39.02

In the previous week, EKF Diagnostics and EKF Diagnostics both had 1 articles in the media. EKF Diagnostics' average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EKF Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NIOX Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

EKF Diagnostics and NIOX Group tied by winning 6 of the 12 factors compared between the two stocks.

How does EKF Diagnostics compare to Tristel?

Tristel (LON:TSTL) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Tristel. Tristel's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
EKF Diagnostics	Neutral

22.5% of Tristel shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tristel has a beta of 0.346, indicating that its stock price is 65% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, indicating that its stock price is 49% less volatile than the broader market.

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
EKF Diagnostics	4.12%	3.01%	5.27%

Tristel has higher earnings, but lower revenue than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	3.97	£6.54M	£16.24	25.25
EKF Diagnostics	£51.56M	2.17	£4.68M	£0.47	55.32

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

EKF Diagnostics beats Tristel on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to INSPECS Group?

INSPECS Group (LON:SPEC) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

EKF Diagnostics has a net margin of 4.12% compared to INSPECS Group's net margin of -2.67%. EKF Diagnostics' return on equity of 3.01% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INSPECS Group	-2.67%	-6.07%	0.45%
EKF Diagnostics	4.12%	3.01%	5.27%

In the previous week, EKF Diagnostics had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.99 beat EKF Diagnostics' score of 0.00 indicating that INSPECS Group is being referred to more favorably in the media.

Company	Overall Sentiment
INSPECS Group	Positive
EKF Diagnostics	Neutral

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 40.00%. EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 34.62%. Given EKF Diagnostics' higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, meaning that its stock price is 49% less volatile than the broader market.

EKF Diagnostics has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSPECS Group	£191.70M	0.57	-£4.11M	-£9.40	N/A
EKF Diagnostics	£51.56M	2.17	£4.68M	£0.47	55.32

0.7% of INSPECS Group shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by company insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

EKF Diagnostics beats INSPECS Group on 11 of the 14 factors compared between the two stocks.

How does EKF Diagnostics compare to Creo Medical Group?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 34.62%. Creo Medical Group has a consensus target price of GBX 40, suggesting a potential upside of 220.51%. Given Creo Medical Group's higher possible upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.17	£4.68M	£0.47	55.32
Creo Medical Group	£6M	10.10	-£25.04M	£1.00	12.48

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. EKF Diagnostics' average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Creo Medical Group	Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by company insiders. Comparatively, 7.0% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

EKF Diagnostics has a beta of 0.513, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
Creo Medical Group	88.33%	9.56%	-20.09%

Summary

EKF Diagnostics beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to BATM Advanced Communications?

EKF Diagnostics (LON:EKF) and BATM Advanced Communications (LON:BVC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, EKF Diagnostics had 1 more articles in the media than BATM Advanced Communications. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for BATM Advanced Communications. EKF Diagnostics' average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
BATM Advanced Communications	Neutral

EKF Diagnostics has a beta of 0.513, indicating that its share price is 49% less volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, indicating that its share price is 25% less volatile than the broader market.

EKF Diagnostics has higher earnings, but lower revenue than BATM Advanced Communications. BATM Advanced Communications is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.17	£4.68M	£0.47	55.32
BATM Advanced Communications	£123.20M	0.34	-£278.26K	-£4.20	N/A

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 14.3% of BATM Advanced Communications shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by insiders. Comparatively, 31.0% of BATM Advanced Communications shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

EKF Diagnostics has a net margin of 4.12% compared to BATM Advanced Communications' net margin of -14.90%. EKF Diagnostics' return on equity of 3.01% beat BATM Advanced Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
BATM Advanced Communications	-14.90%	-22.13%	0.58%

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe EKF Diagnostics is more favorable than BATM Advanced Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
BATM Advanced Communications	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

EKF Diagnostics beats BATM Advanced Communications on 13 of the 15 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EKF vs. The Competition

Export

Metric	EKF Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£111.79M	£5.85B	£7.04B	£2.88B
Dividend Yield	4.65%	1.77%	2.58%	6.09%
P/E Ratio	55.32	25.30	268.83	368.56
Price / Sales	2.17	62.68	588.79	83,672.53
Price / Cash	10.64	33.38	72.26	27.89
Price / Book	1.69	5.82	13.16	7.26
Net Income	£4.68M	£148.67M	£3.45B	£5.89B
7 Day Performance	2.77%	2.07%	1.97%	1.12%
1 Month Performance	2.36%	1.86%	-0.28%	2.56%
1 Year Performance	-11.19%	9.11%	70.56%	70.21%

EKF Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EKF EKF Diagnostics	1.9901 of 5 stars	GBX 26 +3.6%	GBX 35 +34.6%	-16.3%	£111.79M	£51.56M	55.32	356	News Coverage Gap Down
NIOX NIOX Group	2.526 of 5 stars	GBX 61.40 +0.6%	GBX 86 +40.1%	-7.7%	£258.41M	£48.70M	37.44	92	Positive News
TSTL Tristel	N/A	GBX 423.75 -0.3%	N/A	+11.8%	£203.39M	£49.54M	26.09	208
SPEC INSPECS Group	1.0289 of 5 stars	GBX 94 flat	GBX 60 -36.2%	+105.7%	£102.62M	£191.70M	N/A	1,673
CREO Creo Medical Group	N/A	GBX 13.27 -0.2%	GBX 40 +201.4%	-3.9%	£64.47M	£6M	13.27	279

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:EKF) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EKF Diagnostics (EKF) Competitors

EKF vs. NIOX, TSTL, SPEC, CREO, and BVC

How does EKF Diagnostics compare to NIOX Group?

Summary

How does EKF Diagnostics compare to Tristel?

Summary

How does EKF Diagnostics compare to INSPECS Group?

Summary

How does EKF Diagnostics compare to Creo Medical Group?

Summary

How does EKF Diagnostics compare to BATM Advanced Communications?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKF vs. The Competition

EKF Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

EKF Diagnostics (EKF) Competitors

EKF vs. NIOX, TSTL, SPEC, CREO, and BVC

How does EKF Diagnostics compare to NIOX Group?

Is EKF or NIOX more profitable?

Do analysts rate EKF or NIOX?

Which has more volatility & risk, EKF or NIOX?

Which has stronger valuation & earnings, EKF or NIOX?

Does the media prefer EKF or NIOX?

Do institutionals & insiders hold more shares of EKF or NIOX?

Summary

How does EKF Diagnostics compare to Tristel?

Does the media refer more to TSTL or EKF?

Do institutionals and insiders have more ownership in TSTL or EKF?

Which has more volatility and risk, TSTL or EKF?

Is TSTL or EKF more profitable?

Which has stronger valuation & earnings, TSTL or EKF?

Do analysts recommend TSTL or EKF?

Summary

How does EKF Diagnostics compare to INSPECS Group?

Is SPEC or EKF more profitable?

Does the media refer more to SPEC or EKF?

Do analysts rate SPEC or EKF?

Which has more volatility & risk, SPEC or EKF?

Which has higher earnings and valuation, SPEC or EKF?

Do institutionals & insiders have more ownership in SPEC or EKF?

Summary

How does EKF Diagnostics compare to Creo Medical Group?

Do analysts prefer EKF or CREO?

Which has stronger valuation & earnings, EKF or CREO?

Does the media prefer EKF or CREO?

Do insiders & institutionals hold more shares of EKF or CREO?

Which has more volatility & risk, EKF or CREO?

Is EKF or CREO more profitable?

Summary

How does EKF Diagnostics compare to BATM Advanced Communications?

Does the media refer more to EKF or BVC?

Which has more risk and volatility, EKF or BVC?

Which has higher valuation and earnings, EKF or BVC?

Do insiders and institutionals hold more shares of EKF or BVC?

Is EKF or BVC more profitable?

Do analysts prefer EKF or BVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKF vs. The Competition

EKF Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools